Search Results - "Péron, Julien"

A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors by Arnaud‐Coffin, Patrick, Maillet, Denis, Gan, Hui K., Stelmes, Jean‐Jacques, You, Benoit, Dalle, Stephane, Péron, Julien

“…The advent of immune checkpoint‐inhibitors (CPI) has transformed treatment for several cancer types. This review was performed to assess the rate of adverse…”
Get full text

Health-related quality of life analysis in ovarian cancer clinical trials involving PARP inhibitors: a critical methodological perspective by Fiteni, Frédéric, Péron, Julien

“…The poly (ADP-ribose) polymerase inhibitors (PARPi) have yielded significant clinical benefits as maintenance therapy in women with newly diagnosed and…”
Get full text

An extension of generalized pairwise comparisons for prioritized outcomes in the presence of censoring by Péron, Julien, Buyse, Marc, Ozenne, Brice, Roche, Laurent, Roy, Pascal

“…Generalized pairwise comparisons have been proposed to permit a comprehensive assessment of several prioritized outcomes between two groups of observations…”
Get more information

The asymptotic distribution of the Net Benefit estimator in presence of right-censoring by Ozenne, Brice, Budtz-Jørgensen, Esben, Péron, Julien

“…The benefit-risk balance is a critical information when evaluating a new treatment. The Net Benefit has been proposed as a metric for the benefit-risk…”
Get more information

Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better? by Saad, Everardo D, Zalcberg, John R, Péron, Julien, Coart, Elisabeth, Burzykowski, Tomasz, Buyse, Marc

“…Time-to-event end points are the most frequent primary end points in phase III oncology trials, both in the adjuvant and advanced settings. The evaluation of…”
Get more information

ASO Author Reflections: Bi-Directional Chemotherapy Using PIPAC Could Downstage Nonresectable Malignant Peritoneal Mesothelioma Patients to a Complete Resection by Kepenekian, Vahan, Péron, Julien, You, Benoit, Glehen, Olivier

Get full text

Non-resectable Malignant Peritoneal Mesothelioma Treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Plus Systemic Chemotherapy Could Lead to Secondary Complete Cytoreductive Surgery: A Cohort Study by Kepenekian, Vahan, Péron, Julien, You, Benoit, Bonnefoy, Isabelle, Villeneuve, Laurent, Alyami, Mohammad, Bakrin, Naoual, Rousset, Pascal, Benzerdjeb, Nazim, Glehen, Olivier

“…Background Diffuse malignant peritoneal mesothelioma (DMPM) is an aggressive primary peritoneal neoplasia. At diagnosis, few patients are eligible for a…”
Get full text

Integrating Environmental Impact in Health Technology Assessment: An Exploratory Study by Ducrot, Coline, Péron, Julien, Delaye, Matthieu, Pérol, David, Durand-Zaleski, Isabelle, Piffoux, Max

“…To what extent a care pathway, due to its associated pollution, may be more detrimental to future health than beneficial to contemporary patients is still an…”
Get full text

ASO Author Reflections: Colorectal Cancer Patients with Peritoneal Metastases and Other Metastatic Sites Can Benefit from Radical Multifocal Treatment After Comprehensive Evaluation for Accurate Selection by Kepenekian, Vahan, Kefleyesus, Amaniel, Passot, Guillaume, Rousset, Pascal, Péron, Julien, Glehen, Olivier

Get full text

Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors by Maillet, Denis, Corbaux, Pauline, Stelmes, Jean-Jacques, Dalle, Stéphane, Locatelli-Sanchez, Myriam, Perier-Muzet, Marie, Duruisseaux, Michaël, Kiakouama-Maleka, Lize, Freyer, Gilles, Boespflug, Amélie, Péron, Julien

“…Background: The impact of immune-related adverse events (irAE) on survival outcomes after single-agent immune checkpoint inhibitors (ICIs) remains unclear. We…”
Get full text

Advances in the management of peritoneal malignancies by Kepenekian, Vahan, Bhatt, Aditi, Péron, Julien, Alyami, Mohammad, Benzerdjeb, Nazim, Bakrin, Naoual, Falandry, Claire, Passot, Guillaume, Rousset, Pascal, Glehen, Olivier

“…Peritoneal surface malignancies (PSMs) are usually associated with a poor prognosis. Nonetheless, in line with advances in the management of most…”
Get full text

Association of Immunotherapy With Overall Survival in Elderly Patients With Melanoma by Perier-Muzet, Marie, Gatt, Elodie, Péron, Julien, Falandry, Claire, Amini-Adlé, Mona, Thomas, Luc, Dalle, Stephane, Boespflug, Amelie

“…Melanoma treatment has been revolutionized with the development of immune-based therapies that offer durable clinical responses in a subset of patients…”
Get more information

The Benefit-Risk Balance of Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma by Péron, Julien, Giai, Joris, Maucort-Boulch, Delphine, Buyse, Marc

“…The benefit-risk balance of 5-fluorouracil, oxaliplatin, irinotecan, and leucovorin versus gemcitabine assessed using generalized pairwise comparison was…”
Get more information

Restricted Net Treatment Benefit in oncology by Piffoux, Max, Ozenne, Brice, De Backer, Mickaël, Buyse, Marc, Chiem, Jean-Christophe, Péron, Julien

“…The restricted Net Treatment Benefit (rNTB) is a clinically meaningful and tractable estimand of the overall treatment effect assessed in randomized trials…”
Get full text

Influence of Extraperitoneal Metastases on the Curative-Intent Management of Colorectal Peritoneal Metastases by Schell, Frédéric, Kefleyesus, Amaniel, Benzerdjeb, Nazim, Passot, Guillaume, Rousset, Pascal, Omar, Alhadeedi, Villeneuve, Laurent, Péron, Julien, Glehen, Olivier, Kepenekian, Vahan

“…Background Selected patients with colorectal cancer peritoneal metastasis (CRPM) and extraperitoneal disease could be treated radically with a multimodal…”
Get full text

Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study by Colomban, Olivier, Tod, Michel, Leary, Alexandra, Ray-Coquard, Isabelle, Lortholary, Alain, Hardy-Bessard, Anne Claire, Pfisterer, Jacobus, Du Bois, Andreas, Kurzeder, Christian, Burges, Alexander, Péron, Julien, Freyer, Gilles, You, Benoit

“…Regarding cancer antigen 125 (CA-125) longitudinal kinetics during chemotherapy, the actual predictive value of the Gynecologic Cancer Intergroup (GCIG) CA-125…”
Get more information

Using intervention mapping to facilitate and sustain return-to work after breast cancer: protocol for the FASTRACS multicentre randomized controlled trial by Fassier, Jean-Baptiste, Guittard, Laure, Fervers, Béatrice, Rouat, Sabrina, Sarnin, Philippe, Carretier, Julien, Broc, Guillaume, Letrilliart, Laurent, Péron, Julien, Lamort-Bouché, Marion

“…Background Women with breast cancer face many barriers to return to work (RTW) after their cancer. The main objective of the FASTRACS-RCT is to evaluate the…”
Get full text

Impact of acute kidney injury on anticancer treatment dosage and long-term outcomes: a pooled analysis of European Organisation for Research and Treatment of Cancer trials by Péron, Julien, Neven, Anouk, Collette, Laurence, Launay-Vacher, Vincent, Sprangers, Ben, Marreaud, Sandrine

“…The impact of kidney dysfunction on long-term outcomes of patients with advanced cancer remains unclear. Patients with advanced cancer included in trials…”
Get more information

Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting by Corbaux, Pauline, Maillet, Denis, Boespflug, Amélie, Locatelli-Sanchez, Myriam, Perier-Muzet, Marie, Duruisseaux, Michaël, Kiakouama-Maleka, Lize, Dalle, Stéphane, Falandry, Claire, Péron, Julien

“…Age-related immune dysfunction might impair the efficacy of immune checkpoint inhibitors (ICIs) in older patients. We aimed to evaluate the impact of age on…”
Get full text

Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review by Péron, Julien, Maillet, Denis, Gan, Hui K, Chen, Eric X, You, Benoit

“…The Consolidated Standards of Reporting Trials (CONSORT) guidance was extended in 2004 to provide a set of 10 specific and comprehensive guidelines regarding…”
Get more information